- Home
- NBBK vs DAWN Comparison
NBBK vs DAWN Comparison
Compare NBBK & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBBK
- DAWN
- Stock Information
- Founded
- NBBK 1892
- DAWN 2018
- Country
- NBBK United States
- DAWN United States
- Employees
- NBBK N/A
- DAWN N/A
- Industry
- NBBK
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- NBBK
- DAWN Health Care
- Exchange
- NBBK Nasdaq
- DAWN Nasdaq
- Market Cap
- NBBK 714.5M
- DAWN 624.8M
- IPO Year
- NBBK N/A
- DAWN 2021
- Fundamental
- Price
- NBBK $18.83
- DAWN $7.20
- Analyst Decision
- NBBK Buy
- DAWN Strong Buy
- Analyst Count
- NBBK 1
- DAWN 7
- Target Price
- NBBK $20.00
- DAWN $27.86
- AVG Volume (30 Days)
- NBBK 179.5K
- DAWN 2.1M
- Earning Date
- NBBK 07-23-2025
- DAWN 08-05-2025
- Dividend Yield
- NBBK 1.49%
- DAWN N/A
- EPS Growth
- NBBK 341.36
- DAWN N/A
- EPS
- NBBK 1.33
- DAWN N/A
- Revenue
- NBBK $179,117,000.00
- DAWN $187,638,000.00
- Revenue This Year
- NBBK N/A
- DAWN $16.42
- Revenue Next Year
- NBBK N/A
- DAWN $47.52
- P/E Ratio
- NBBK $14.18
- DAWN N/A
- Revenue Growth
- NBBK 28.24
- DAWN 2190.50
- 52 Week Low
- NBBK $15.09
- DAWN $5.64
- 52 Week High
- NBBK $21.05
- DAWN $16.76
- Technical
- Relative Strength Index (RSI)
- NBBK 62.71
- DAWN 62.39
- Support Level
- NBBK $17.93
- DAWN $6.71
- Resistance Level
- NBBK $18.36
- DAWN $7.12
- Average True Range (ATR)
- NBBK 0.44
- DAWN 0.32
- MACD
- NBBK 0.10
- DAWN 0.10
- Stochastic Oscillator
- NBBK 97.40
- DAWN 85.05
About NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, and consumer loans.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.